

Supplemental Amendment under 37 C.F.R. § 1.111
Application No. 10/511,174

Q84084

REMARKS


This Supplemental Amendment is being submitted at the Examiner's request.

Claim 25 is amended by deleting "prophylaxis" and by incorporating the subject matter of claims 27-30. Claims 26-30 are canceled herein. No new matter is presented.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Jennifer M. Hayes
Registration No. 40,641

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 27 2007

PATENT APPLICATION**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q84084

Yoshiyuki MATSUMOTO, et al.

Appln. No.: 10/511,174

Group Art Unit: 1624

Confirmation No.: 1998

Examiner: Kasha Y. HABTE

Filed: October 15, 2004

For: PIPERIDINE DERIVATIVES WITH CCR3 ANTAGONISM

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on

April 23, 2007:

REMARKS

An Examiner's Interview Summary Record (PTO-413) has not yet been received.

The interview was initiated by the Examiner. Therefore, no further recordation by the Applicant is believed to be required.

During the interview, the following was discussed:

1. Brief description of exhibits or demonstration: None.
2. Identification of claims discussed: 25
3. Identification of art discussed: None.

Statement of Substance of Interview
Application No. 10/511,174

Q84084

4. Identification of principal proposed amendments: The Examiner suggested that "prophylaxis" should be deleted from claim and that the claim should be amended to recite specific diseases and/or conditions.

5. Brief Identification of principal arguments: None.

6. Indication of other pertinent matters discussed: None.

7. Results of Interview: See Supplemental Amendment filed herewith.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Jennifer M. Hayes
Registration No. 40,641

Date: April 27, 2007